Welcome to our dedicated page for Entera Bio news (Ticker: ENTX), a resource for investors and traders seeking the latest updates and insights on Entera Bio stock.
Entera Bio Ltd (ENTX) is a clinical-stage biopharmaceutical company pioneering oral peptide therapies for chronic conditions like osteoporosis and hypoparathyroidism. This page provides investors and industry professionals with timely updates on the company’s clinical trials, regulatory milestones, and strategic initiatives.
Access the latest press releases and news about Entera Bio’s proprietary drug delivery platform, which aims to transform treatment paradigms by replacing injectable therapies with oral alternatives. Track developments across their pipeline, including phase advancements for lead candidates and collaborations advancing oral macromolecule research.
Key updates include progress on EB613 for bone health, EB612 for hormone regulation, and innovations in peptide absorption technology. Bookmark this page to stay informed about financial disclosures, partnership announcements, and scientific breakthroughs directly from the source.
Entera Bio Ltd. (NASDAQ: ENTX) announced positive results from its completed Phase 2 trial of EB613, an oral formulation of human parathyroid hormone (PTH) aimed at treating osteoporosis. Key findings showed a significant placebo-adjusted increase of 3.78% in lumbar spine bone mineral density (BMD) after six months of treatment with the 2.5 mg dosage. Additionally, increases in BMD at the femoral neck and total hip were noted. The pivotal Phase 3 registration study is expected to commence in 2022. The safety profile was consistent with injectable PTH, with no serious adverse events reported.
Entera Bio Ltd. (NASDAQ: ENTX) announced its selection for a late-breaking oral presentation at the ASBMR Annual Meeting, showcasing results from its Phase 2 study on EB613 for treating osteoporosis in postmenopausal women. The presentation will highlight the 6-month bone mineral density (BMD) results, confirming dose-related efficacy. Scheduled for October 4, 2021, this position aims to attract interest from potential clinical investigators and prescribers. Entera is gearing up for a pivotal Phase 3 study, as CEO Spiros Jamas noted positive peer reviews enhancing the presentation's significance.
On August 23, 2021, Entera Bio Ltd. (NASDAQ: ENTX) announced its upcoming annual shareholders meeting scheduled for October 4, 2021. Entera is focused on developing orally delivered large molecule therapeutics to address unmet medical needs in areas where injectable therapies face adoption challenges. Its leading candidates, EB613 for osteoporosis and EB612 for hypoparathyroidism, are currently in clinical development. The company also collaborates with Amgen Inc. to leverage its proprietary oral delivery technology.
Entera Bio Ltd. (NASDAQ: ENTX) announced that CEO Spiros Jamas will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 3:30 pm ET. The conference runs from September 13-15, 2021, in New York. Entera focuses on innovative oral delivery systems for large molecule therapeutics, addressing significant unmet medical needs. Their lead candidates include EB613 for osteoporosis and EB612 for hypoparathyroidism, currently in clinical development. The company also collaborates with biopharma firms, including Amgen.
Entera Bio Ltd. (NASDAQ: ENTX) announced positive results from its Phase 2 clinical trial of EB613, an oral therapy for osteoporosis, achieving primary and key secondary endpoints. The trial demonstrated a 3.78% increase in lumbar spine bone mineral density after six months. The company is preparing for an End of Phase 2 meeting with the FDA to advance to a pivotal Phase 3 study, expected to start in Q2 2022. Financially, Entera reported $266,000 in revenue for the first half of 2021, with a net comprehensive loss of $14.6 million, or $0.63 per share.
Entera Bio Ltd. (NASDAQ: ENTX) will report its business and financial results for Q2 2021 on August 16, 2021, at 6:30 AM ET. A conference call led by management will follow at 8:30 AM EDT, allowing stakeholders to engage in a Q&A session. Entera is focused on developing orally delivered large molecule therapeutics, particularly EB613 for osteoporosis and EB612 for hypoparathyroidism, which are currently in clinical development. The company has completed a phase 2 study for EB613 and collaborates with Amgen for technology licensing.
Entera Bio Ltd. (NASDAQ: ENTX) announced that its Phase 2 clinical trial for oral EB613, aimed at treating osteoporosis, met its primary endpoint by significantly increasing P1NP, a bone formation marker, at three months. This positions EB613 as a potential first oral anabolic agent for osteoporosis, addressing the unmet need for injectable alternatives like Forteo®. Full three-month data will be presented at the ASBMR Annual Meeting in October. Entera plans to initiate a pivotal Phase 3 trial against Forteo in 2022, highlighting the promising outlook for EB613.
Entera Bio Ltd. (NASDAQ: ENTX) announced a conference call to discuss the results of its successful Phase 2 clinical trial of EB613 for osteoporosis treatment. EB613 is an oral formulation of human parathyroid hormone (1-34) intended to be the first oral anabolic product for osteoporosis patients. The call will include insights from Dr. Liana Tripto-Shkolnik and Entera's leadership team, scheduled for June 30, 2021. Entera aims to address the challenges of delivering large molecules orally, with EB613 and EB612 currently in Phase 2 development.
Entera Bio Ltd. (NASDAQ: ENTX) announced significant results from its Phase 2 trial of EB613, an oral treatment for osteoporosis. The 2.5 mg dose showed a 3.78% increase in lumbar spine BMD after 6 months, exceeding placebo. The study met its primary endpoint with a statistically significant rise in P1NP, a bone formation biomarker. EB613 demonstrated an excellent safety profile, with no serious drug-related adverse events. An End of Phase 2 meeting with the FDA is anticipated to discuss advancing to a pivotal Phase 3 study against Forteo, highlighting EB613's potential as the first oral anabolic therapy for osteoporosis.
Entera Bio Ltd. (NASDAQ: ENTX) has been granted a critical European patent for its oral delivery technology aimed at large molecule therapeutics, particularly for osteoporosis and hypoparathyroidism. This patent enhances Entera's intellectual property portfolio, facilitating its leadership in the oral delivery of proteins. The company anticipates releasing final bone mineral density (BMD) results from its Phase 2 study of EB 613 in Q2 2021, with plans to pursue a pivotal Phase 3 study next year, provided data are favorable.
FAQ
What is the current stock price of Entera Bio (ENTX)?
What is the market cap of Entera Bio (ENTX)?
